These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

454 related items for PubMed ID: 16444866

  • 1. ADMA and hyperhomocysteinemia.
    Dayal S, Lentz SR.
    Vasc Med; 2005 Jul; 10 Suppl 1():S27-33. PubMed ID: 16444866
    [Abstract] [Full Text] [Related]

  • 2. Pharmacotherapies and their influence on asymmetric dimethylargine (ADMA).
    Maas R.
    Vasc Med; 2005 Jul; 10 Suppl 1():S49-57. PubMed ID: 16444869
    [Abstract] [Full Text] [Related]

  • 3. ADMA: its role in vascular disease.
    Cooke JP.
    Vasc Med; 2005 Jul; 10 Suppl 1():S11-7. PubMed ID: 16444864
    [Abstract] [Full Text] [Related]

  • 4. Tissue-specific downregulation of dimethylarginine dimethylaminohydrolase in hyperhomocysteinemia.
    Dayal S, Rodionov RN, Arning E, Bottiglieri T, Kimoto M, Murry DJ, Cooke JP, Faraci FM, Lentz SR.
    Am J Physiol Heart Circ Physiol; 2008 Aug; 295(2):H816-25. PubMed ID: 18567702
    [Abstract] [Full Text] [Related]

  • 5. Endothelial dysfunction in patients with peripheral arterial disease and chronic hyperhomocysteinemia: potential role of ADMA.
    Sydow K, Hornig B, Arakawa N, Bode-Böger SM, Tsikas D, Münzel T, Böger RH.
    Vasc Med; 2004 May; 9(2):93-101. PubMed ID: 15521698
    [Abstract] [Full Text] [Related]

  • 6. Plasma concentration of asymmetric dimethylarginine, an endogenous inhibitor of nitric oxide synthase, is elevated in monkeys with hyperhomocyst(e)inemia or hypercholesterolemia.
    Böger RH, Bode-Böger SM, Sydow K, Heistad DD, Lentz SR.
    Arterioscler Thromb Vasc Biol; 2000 Jun; 20(6):1557-64. PubMed ID: 10845872
    [Abstract] [Full Text] [Related]

  • 7. Homocysteine impairs the nitric oxide synthase pathway: role of asymmetric dimethylarginine.
    Stühlinger MC, Tsao PS, Her JH, Kimoto M, Balint RF, Cooke JP.
    Circulation; 2001 Nov 20; 104(21):2569-75. PubMed ID: 11714652
    [Abstract] [Full Text] [Related]

  • 8. Association of asymmetric dimethylarginine and endothelial dysfunction.
    Böger RH.
    Clin Chem Lab Med; 2003 Nov 20; 41(11):1467-72. PubMed ID: 14656027
    [Abstract] [Full Text] [Related]

  • 9. Hyperhomocysteinemia, endothelial dysfunction, and cardiovascular risk: the potential role of ADMA.
    Lentz SR, Rodionov RN, Dayal S.
    Atheroscler Suppl; 2003 Dec 20; 4(4):61-5. PubMed ID: 14664904
    [Abstract] [Full Text] [Related]

  • 10. Insulin resistance: potential role of the endogenous nitric oxide synthase inhibitor ADMA.
    Sydow K, Mondon CE, Cooke JP.
    Vasc Med; 2005 Jul 20; 10 Suppl 1():S35-43. PubMed ID: 16444867
    [Abstract] [Full Text] [Related]

  • 11. Asymmetric dimethylarginine (ADMA) and cardiovascular disease: insights from prospective clinical trials.
    Böger RH.
    Vasc Med; 2005 Jul 20; 10 Suppl 1():S19-25. PubMed ID: 16444865
    [Abstract] [Full Text] [Related]

  • 12. Plasma asymmetric and symmetric dimethylarginine in a rat model of endothelial dysfunction induced by acute hyperhomocysteinemia.
    Magné J, Huneau JF, Borderie D, Mathé V, Bos C, Mariotti F.
    Amino Acids; 2015 Sep 20; 47(9):1975-82. PubMed ID: 25792109
    [Abstract] [Full Text] [Related]

  • 13. Protection of DDAH2 overexpression against homocysteine-induced impairments of DDAH/ADMA/NOS/NO pathway in endothelial cells.
    Liu LH, Guo Z, Feng M, Wu ZZ, He ZM, Xiong Y.
    Cell Physiol Biochem; 2012 Sep 20; 30(6):1413-22. PubMed ID: 23171931
    [Abstract] [Full Text] [Related]

  • 14. Asymmetric dimethylarginine, an endogenous inhibitor of nitric oxide synthase, explains the "L-arginine paradox" and acts as a novel cardiovascular risk factor.
    Böger RH.
    J Nutr; 2004 Oct 20; 134(10 Suppl):2842S-2847S; discussion 2853S. PubMed ID: 15465797
    [Abstract] [Full Text] [Related]

  • 15. Role of dimethylarginine dimethylaminohydrolases in the regulation of endothelial nitric oxide production.
    Pope AJ, Karrupiah K, Kearns PN, Xia Y, Cardounel AJ.
    J Biol Chem; 2009 Dec 18; 284(51):35338-47. PubMed ID: 19820234
    [Abstract] [Full Text] [Related]

  • 16. Dimethylarginine dimethylaminohydrolase inhibition and asymmetric dimethylarginine accumulation contribute to endothelial dysfunction in rats exposed to glycosylated protein: effects of aminoguanidine.
    Yin QF, Fu SH, He P, Xiong Y.
    Atherosclerosis; 2007 Jan 18; 190(1):53-61. PubMed ID: 16533509
    [Abstract] [Full Text] [Related]

  • 17. Vascular endothelium is the organ chiefly responsible for the catabolism of plasma asymmetric dimethylarginine--an explanation for the elevation of plasma ADMA in disorders characterized by endothelial dysfunction.
    McCarty MF.
    Med Hypotheses; 2004 Jan 18; 63(4):699-708. PubMed ID: 15325021
    [Abstract] [Full Text] [Related]

  • 18. Overexpression of dimethylarginine dimethylaminohydrolase inhibits asymmetric dimethylarginine-induced endothelial dysfunction in the cerebral circulation.
    Dayoub H, Rodionov RN, Lynch C, Cooke JP, Arning E, Bottiglieri T, Lentz SR, Faraci FM.
    Stroke; 2008 Jan 18; 39(1):180-4. PubMed ID: 18063827
    [Abstract] [Full Text] [Related]

  • 19. Asymmetric dimethylarginine (ADMA): a key regulator of nitric oxide synthase.
    Böger RH, Vallance P, Cooke JP.
    Atheroscler Suppl; 2003 Dec 18; 4(4):1-3. PubMed ID: 14664896
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 23.